PharmaSource Podcast

How to Select and Sustain an Early-Stage CDMO Partnership

At CDMO Live Europe 2026, Giulio Cavalli, Principal Lead External Manufacturing, J&J Innovative Medicine; Neil Stevenson, Director, CMC Logic Consultancy; Marine Joly Bat

What Changes When Pharma Outsources Outcomes, Not Just People?

“Traditional staff augmentation says, ‘Here are the people you asked for.’ An outcome-led model says, ‘Here is the service or capability you asked for, and we are account

Europe Needs to Pick a Side: Why Geopolitics Is Forcing a Rethink of Pharma Supply Network Design

Sponsored by Blue Jet Healthcare, this panel at CDMO Live Europe 2026 brought together Bernhard Boehm, Head of External Manufacturing Animal Health, Boehringer Ingelheim;

AI in Biopharma Manufacturing: Why Build-or-Buy Is the Wrong First Question

“AI is marketed as such an approachable, ubiquitous thing that everybody thinks they can vibe code it. Unfortunately, a lot of companies are starting to think that way,”

What CDMOs Get Wrong About AI for Bioprocessing, According to Sapiens Health’s Seungik Cho

“How good is your AI model? That’s the wrong question. The right question is: what does your AI model actually help your company do?” Seungik Cho, founder of Sapiens Hea

How to Identify a Root Cause Without Delay: Interlabor's Troubleshooting Framework

At CDMO Live Europe 2026, Dr. Olivier Aebischer, Deputy CEO at Interlabor Belp AG, demonstrated how a structured, dual-path analytical approach can identify manufacturing

How ExoZymes Is Running a 10-CDMO RFP for CDMO Selection

“We can adjust and be flexible around equipment configuration, but we can’t be flexible around what is a clear communicator and an honest partner.” Damien Perriman is Ch

How EU Sustainability Regulations Are Reshaping CDMO Manufacturing

“Rather than saying that there’s a gap from the industry, I think there’s a listening gap from our governments.” Neha Dave is an independent EU Government Affairs Adviso

"Stop Talking About Resilience in the Future Tense": What Pharma Actually Wants From CDMOs

Moderated by Raman Sehgal, Host of Molecule to Market, this opening panel at CDMO Live Europe 2026 brought together Melanie Wamsler, External Network Strategy Lead, Taked

Abzena on AOCs: Building US Capacity to Compete With China

“There isn’t enough capacity for antibody-oligo conjugates out there today, full stop,” says Geoff Glass, CEO of Abzena. “And it’s really because of the volume requiremen

“Mexico Is the New China”: Reshoring Institute Executive Director Rosemary Coates on the Future of Pharmaceutical Reshoring

“If you look at the employment numbers in the manufacturing sector, it’s been absolutely flat for two years. The political noise has not driven that big wave of reshoring

How Cognition Therapeutics Cut Cost of Goods by 85% Through Smarter CMC Strategy

“No one is going to care about your project as much as you do.”  Steven Weissman is Vice President and Head of CMC at Cognition Therapeutics, a small pharma company outs

How to Connect a CDMO Network Without Starting From Scratch

“Digital collaboration is a competitive advantage for everyone — for CDMOs and CMOs, it’s not a question of if you’re going to do it, it’s when. So how do you get ready f

CDMO Relationship Management Across the Americas: Why Culture Changes Everything

“When we go to an external partner, we need to show up as one single aligned organization. If we’re not aligned internally, the CMO ends up becoming the referee.” In ph

How To Complete a Dual-Site Biologics Tech Transfer in 90 Days

At CDMO Live Europe 2026, Jeff Mason, VP and Head of US Sales at Samsung Biologics, demonstrated a risk-based, parallel approach to dual-site technology transfer that del

When Outsourcing Goes Wrong

When relationships with contract manufacturers break down, the cause is rarely just the contract manufacturer. A panel of three sponsor-side executives examined the warni

Why the Least Expensive CDMO Could Cost the Most

“The least expensive CDMO on the first day of bidding may not be the optimum value CDMO three years later.” Choosing a contract development and manufacturing organizatio

“One Size Doesn’t Fit All”: CRAMSN COO on Serving Biotechs and Big Pharma Under One Roof

At CDMO Live Europe, Dr. Vijay Vittal Mathad, Chief Operating Officer of CRAMSN Research Park, outlined how a genuine end-to-end CDMO model reduces friction across the dr

How To Deliver a High-Concentration Bispecific Antibody Tox Batch in 4 Months

Leon Tian, Director of US Project Management, ProBio, walked through the cell line development, high-concentration formulation, and purification workflow, delivering a bi

Novartis’ Win-Win Approach to Greener Drug Development

“Environmental Sustainability can be a substantial differentiator for CDMOs” Jürgen Wieland, Development Environmental Sustainability Lead at Novartis, is engaged to int